Combined PDE4+MEK inhibition shows antiproliferative effects in NRASQ61 mutated melanoma preclinical models. Louveau B, Reger De Moura C, Jouenne F, Sadoux A, et al. Melanoma Res 2023 Dec 22. doi: 10.1097/CMR.0000000000000950.

Read + Share

Amedeo Smart

Independent Medical Education

Louveau B, Reger De Moura C, Jouenne F, Sadoux A, et al. Combined PDE4+MEK inhibition shows antiproliferative effects in NRASQ61 mutated melanoma preclinical models. Melanoma Res 2023 Dec 22. doi: 10.1097/CMR.0000000000000950.
PMID: 38141200